COSMETIC OR DERMATOLOGICAL PEPTIDE-BASED TREATMENT OF THE SKIN AND ITS INTEGUMENTS

Abstract

The treatment according to the invention provides for the use of at least one peptide of general Formula X-(Xaa).sub.nK*TSK*X′aa-(Xaa).sub.mZ for a non-therapeutic cosmetic treatment of keratin materials of the skin and of its integuments, including treatment of the epidermis, scalp, hair, and nails, where X, Xaa, K*, X′aa, Z, m and n are as defined. A preferred peptide is Pal-KTSKS.

Claims

1.-35. (canceled)

36. A method of treating keratinic materials of skin and its integuments, comprising applying to an epidermis, scalp, hair and nails in need thereof of at least one peptide of the following general Formula 1 or a composition comprising said at least one peptide and a physiologically acceptable medium:
X—(Xaa).sub.nK*TSK*X′aa-(Xaa).sub.m-Z  (1) wherein in general Formula 1: K* is chosen from lysine, hydroxylysine, ornithine, diaminobutyric acid or diaminopropionic acid or their formyl, acetyl, trifluoroacetyl, methanesulfonyl or succinyl derivatives, the two K* possibly being identical or different; (Xaa).sub.n and (Xaa).sub.m correspond independently of one another to a sequence of n or m amino acids Xaa chosen independently of one another from G, A, P, V, L, I and F, with n and m being integers which may be equal or different between 0 and 5; X′aa is chosen from threonine and serine; at the N-terminal end X is chosen from H, —CO—R.sup.1, —SO.sub.2-R.sup.1 or a biotinoyl group; at the C-terminal end Z is chosen from OH, OR.sup.1, NH.sub.2, NHR.sup.1 or NR.sup.1R.sup.2; and R.sup.1 and R.sup.2 are, independently of one another, chosen from an alkyl, aryl, aralkyl, alkylaryl, alkoxy, saccharide and aryloxy group, which may be linear, branched, cyclic, polycyclic, unsaturated, hydroxylated, carbonylated, phosphorylated and/or sulfurized, said group having from 1 to 24 carbon atoms and possibly having in its backbone one or more O, S and/or N heteroatoms.

37. The method according to claim 36, wherein the treatment is a cosmetic treatment for: treating the epidermal stratum corneum for protecting the epidermis and scalp from external aggressions liable to cause damage, such as microorganisms, radiation and molecules; smoothing epidermis relief; uniformizing skin epidermis; treating skin pores; treating oily and/or acne-prone skins; and/or preserving the balance of the skin microbiota.

38. The method according to claim 37, for preventing cutaneous redness, irritation, and tightness, and/or or premature aging of the epiderm, for preventing the scalp against the appearance of dandruff by inhibiting the development of the yeasts responsible for a dandruff condition of the Malassezia genus and/or for treating epidermis dehydration.

39. The method according to claim 37, for smoothing acne atrophic traces.

40. The method according to claim 37, for treating coloured marks.

41. The method according to claim 40, for treating residual acne lesion-coloured marks.

42. The method according to claim 37, wherein the appearance of acne is prevented, by inhibiting the multiplication of the P. acnes bacteria responsible for acne.

43. The method according to claim 36, for an antimicrobial and/or anti-inflammatory treatment.

44. The method according to claim 43, for inhibiting the growth of the Propionibacterium acnes bacteria responsible for acne and/or yeasts of the Malassezia genus responsible for a dandruff state.

45. The method according to claim 43 for an anti-inflammatory composition suitable for soothing sensitive and irritated skin.

46. The method according to claim 43 for treating acne, psoriasis, dermatitis and/or eczema.

47. The method according to claim 36, wherein the at least one peptide is used in a vectorized form, being bound, incorporated or adsorbed on/to macro-, micro- or nanoparticles. such as capsules, spheres, liposomes, oleosomes, chylomicrons, sponges, in the form of micro- or nano-emulsions, or adsorbed for example on powdery organic polymers, talcs, bentonites, spores or exins and other inorganic or organic supports.

48. The method according to claim 36, wherein K* is a lysine or an ornithine.

49. The method according to claim 36, wherein X′aa is serine.

50. The method according to claim 36, wherein n and m are independently of each other 0 or 1 or 2.

51. The method according to claim 36, wherein the peptide is modified in the N-terminal position and/or in the C-terminal position.

52. The method according to claim 36, wherein R.sup.1 and/or R.sup.2 is an alkyl chain of 1 to 24 carbon atoms.

53. The method according to claim 52, wherein R.sup.1 and/or R.sup.2 is an alkyl chain of 3 to 24 carbon atoms.

54. The method according to claim 36 wherein X is an acyl group CO—R.sup.1 and Z is chosen from OH, OMe, OEt and NH.sub.2.

55. The method according to claim 36 wherein said peptide is Pal-KTSKS (SEQ ID No 5).

Description

DETAILED DESCRIPTION

[0093] The present invention will be better understood in the light of the following description of an embodiment and of in vitro tests.

[0094] A—Example of Preparation of the Pal-KTSKS (SEQ ID No 5) Peptide According to the Invention

[0095] The Pal-KTSKS peptide is prepared by peptide synthesis. A serine is coupled with a resin via its terminal acid function (with a coupling agent, for example DCC (diclyclohexylcarbodiimide)/NHS (N-hydroxysuccinimide) or HBTU (2-(1H-benzotriazol-1-yl) -1, 1, 3, 3-tetramethyluronium hexafluorophosphate)/HOBT (1-hydroxy-benzotriazole)). The serine thus protected is then reacted with a lysine derivative in the presence of a coupling agent, then the same operation is carried out to add a second serine and a threonine, then in the same way to add the second lysine. The latter is then acylated on its amine function with an activated palmitic acid derivative (palmitoyl chloride for example) in the presence of a base. The peptide chain is cleaved from the resin in an acidic medium and after precipitation, washing and drying, the product palmitoyl-lysyl-threonyl-serine-lysyl-serine is obtained in solid form.

[0096] The peptide according to the invention can also be prepared by a biotechnological route, via a microorganism capable of producing it at least partially.

[0097] B—Preparation Example of a Cosmetic Active Ingredient According to the Invention Comprising the Pal-KTSKS (SEQ ID No 5)

[0098] The Pal-KTSKS peptide is amphiphilic, the Pal chain being hydrophobic and the peptide part being hydrophilic. The peptide, for example at 1200 ppm, is dissolved in a water/glycol matrix (the medium) with suitable surfactants. The active ingredient can be prepared in a concentration range of 100 to 10,000 ppm of the peptide(s) of the invention.

[0099] C—In-Vitro Efficacy Tests

[0100] I—on the Preferred Peptide of the Invention: The Pal-KTSKS

[0101] 1—Description of Performed Tests

[0102] They were carried out on epidermis cells: normal human keratinocytes (NHK) or human keratinocytes (HaCaT), and dermis cells: normal human fibroblasts (NHF). A test was carried out on a culture of the Propionibacterium acnes bacterium. The peptide was tested in solution in an inert solvent at concentrations recommended for a cutaneous use.

[0103] 1.1—Immuno-Enzymatic Assays (ELISA) on Normal Human Keratinocyte (NHK) Culture

[0104] Principle: NHKs in culture and at confluence are brought into contact with the peptide of the invention at different concentrations for 24 hours in a medium allowing their survival. Then the cell layers are irradiated with UVB (light stress, intended to mimic an experimental cutaneous micro-inflammation) in a physiological buffer and again brought into contact with the products to be tested for 24 hours. At the end of this incubation, the culture media are assayed by ELISA to evaluate the amounts of pro-inflammatory mediators (PGE2 and IL-6) produced by these cells in response to irradiation. The results are compared to the control. A decrease in the amount of mediators produced will be interpreted as a limitation of damages related to inflammation. An estimate of the cell number is made on the attached layer to reduce the assay results to the number of cells. A study of variances and a Student t test are carried out to judge the significance of the results.

[0105] This same type of test was carried out on a HaCaT culture (human keratinocyte line), but without the irradiation step, with a contact time of 72 hours between the cells and the peptide of the invention and an ELISA assay of hyaluronic acid on the culture medium.

[0106] 1.2—DNA Microarray-Technology NHK Culture

[0107] Principle: the peptide according to the invention at 9 ppm is brought into contact for 24 hours with confluent NHKs (versus control case). Then the NHKs layers are rinsed, and the cells are crushed to extract their mRNA. These mRNAs are then converted into DNA sequences which are analyzed after deposition on DNA chips and amplification by a method similar to qRT-PCR (Real-time Quantitative Reverse Transcription Polymerase Chain Reaction). The mRNA variations due to the peptide are compared to the control case (the solvent of the peptide). The results are expressed as an expression ratio between the treated case and the control case. A ratio greater than 2 is considered to be induction of gene expression (+50% compared to the control).

[0108] 1.3—Immuno-Enzymatic Tests on Normal Human Fibroblasts (NHF) Culture

[0109] Principle: Normal Human Fibroblasts (NHF) are cultured in 24-well plates for 24 hours in the proliferation medium until confluence. The cells are then brought into contact or not (control case) with the preferred peptide according to the invention for 3 days in a medium without serum. The culture media are collected and the concentrations of various elements of the dermis or the basement membrane (PIP (carboxy-terminal propeptide of procollagen type I), collagen I, collagen IV, fibronectin) are measured by ELISA assays. An estimate of cell viability is also carried out at the end of culture, in order to weight the data from the ELISA, using an assay with the Hoechst 33258 reagent (DNA intercalator). A study of variances and a Student t test for paired series were carried out to judge the significance of the results.

[0110] 1.4—Propionibacterium acnes Growth Inhibition Test

[0111] Principle: Suspensions of Propionibacterium acnes of equivalent density are cultured in a suitable medium in the presence (test case) or absence (control case) of the preferred peptide according to the invention, in anaerobic condition, at 37° C. Samples are taken at regular intervals to measure the OD at 600 nm, to follow the growth of the bacterial population over time. The growth curve of each culture can therefore be established.

[0112] 1.5—Scratch Test on HaCaTs

[0113] Principle: HaCats are inoculated in a 6-well plate in a suitable medium until confluence. 24-hour contact with the peptide according to the invention (test cases) or its excipient (control case) in the culture medium is then carried out. After this first step, wounds are made on the cell layers in the experimental wells (with a dedicated tool to make reproducible and small wounds); two wells per case are dedicated to cell counting; rinsing with PBS and an addition of culture medium with or without the peptide according to the invention depending on the case, in the presence or absence of Propionibacterium acnes (100 bacteria for 1 HaCaT cell) are carried out. Photos are taken (to calculate the area of the wound at T0 over a specific area). The cultures are stopped after 24 hours of incubation and photos are taken on the same areas as at T0. A photo processing software (Image J) can calculate for each case the area at T0 and the area recolonized by cells, 24 hours after injury, and establish a ratio.

[0114] 2—Results

[0115] 2.1—Action at the Level of the Epidermis

[0116] 2.1.1—Improvement of the Epidermal Barrier and Harmonization of the Maturation of the Epidermis

[0117] The horny layer (also called cornified layer or envelop, or stratum corneum) is an assembly of great complexity associating, on the one hand, cells without nucleus, flat and strongly linked to each other and, on the other hand, lipids and proteins whose composition and assembly provide the unique properties of this structure very resistant to physical, chemical and biological attacks from the environment.

[0118] The keratinocytes gradually mature by acquiring a very resistant outer shell formed of proteins called involucrin, loricrin and periplakin, linked together thanks to the intervention of transglutaminases, enzymes sensitive to calcium. In addition, SPRRs (Small Proline Rich Region Proteins), other proteins involved in the maturation and homeostasis of the stratum corneum, serve to strengthen this protein shell by creating flexible but resistant bridges between proteins, there again thanks to the transglutaminase activity. There are also LCEs (Late Cornified Envelope Proteins) which are among the last components to be bridged during the maturation phase. LCEs form a large family largely linked to the epidermis with a structural but also functional role in the control of microbial attacks. LCE3A is notably capable of acting in the control of populations of different skin germs (detailed in point 2.1.3 below). Their action is particularly interesting as it is coupled with a limitation of the anarchic proliferation of keratinocytes, an increase in their maturation in the formation of the stratum corneum and the moderation of inflammatory phenomena, phenomena observed in lesions such as psoriasis, dermatitis, or eczema (detailed in point 2.1.5 below).

[0119] Furthermore, ceramides are of great importance in the formation of the stratum corneum and its proteolipid matrix, hence the importance of cosmetic active agents stimulating their synthesis and/or their deposition at the level of the stratum corneum.

[0120] A good barrier function is also very dependent on filaggrin, and filaggrin-2 produced by keratinocytes where they undergo significant metabolism. They are used for a time to stabilize the corneocyte by attaching themselves to the keratins.

TABLE-US-00001 TABLE 1 Variation compared to the control in the expression of genes encoding proteins of epidermal differentiation and formation of the stratum corneum (DNA-Microarray) Expressed gene Variation Name and function of the protein LOR ×193 Loricrin: major protein of the stratum corneum which confers its cohesion/rigidity; linked to the other proteins of the layer by the enzymatic action of TGM3 and TGM1 (see below). IVL ×8.43 Involucrin: major protein also of the stratum corneum; confers its cohesion/rigidity; linked to other proteins in the stratum corneum by the enzymatic action of TGM1 (see below). PPL ×4.12 Periplakin: serves as a link between the desmosome and the stratum corneum; interacts with the intermediate filaments. TGM1 ×4.66 Transglutaminase-1: enzyme that binds envoplakin, periplakie and involucrin to form the stratum corneum. These crosslinks between different structural proteins of the stratum corneum ensure rigidity by relying on desmosomes. This same enzyme catalyzes the attachment of these units to those produced by TGM3 (see below). In addition, it catalyzes the attachment of w- hydroxyceramides to proteins already bound together in the stratum corneum, which helps maintain hydration of the stratum corneum. TGM3 ×132 Transglutaminase-3: enzyme binding loricrin to SPRRs (see below). TGM5 ×27.1 Transglutaminase-5: enzyme that binds envoplakin, periplakin and involucrin together to create a rigid structure of the stratum corneum. Allows anchoring of these plaques to the desmosomes. SPRR1A ×2.00 Small Proline Rich Region Proteins: the proteins of the SPRR2A ×24.09 maturation and homeostasis of the stratum corneum, serve to SPRR2C ×15.35 strengthen the protein shell of the corneocyte by creating SPRR2E ×12.48 flexible but resistant bridges between proteins (loricrin) thanks SPRR2F ×15.29 to the activity of transglutaminases. SPRR2D ×23.97 SPRR2B ×451.61 SPRR2G ×687.57 SPRR3 ×48.62 SPRR4 ×23.16 LCE3A ×306.86 Late Cornified Envelop Proteins: they are the last components LCE3B ×324.01 to be bridged during the maturation phase in the stratum LCE3D ×1454.67 corneum. They are also believed to have a role in antimicrobial LCE3E ×612.90 defense. LCE2C ×37.7 CRNN ×258.60 Cornulin: marker of the terminal epidermal differentiation. Strongly reduced in case of eczema. TCHH ×2.39 Trichohyaline: structural protein that helps strengthen the barrier by cross-bridging with other proteins in the stratum corneum using the enzyme TGM1; is used in particular to connect the keratins of the intermediate filaments. CALML5 ×10.73 Calmodulin-like protein-5: controls the differentiation of the epidermis, its inhibition leads to barrier defects and abolishes the production of keratohyalin granules. Forms a complex with calcium; calmodulins provide control over a large number of enzymes, ion channels, aquaporins and other proteins. FLG ×25.40 Filaggrin: see above. FLG2 ×197 Filaggrine-2: another member of the FLG-Like protein family- present on the human epidermal differentiation complex. PRSS8 ×2.74 Serine protease-8: essential for the formation of epithelial barriers, a co-factor of matriptase; cleaves profillagrin into filaggrin and helps hydrate the stratum corneum. ASPRV1 ×430 Skin aspartic protease: cleaves profillagrin into filaggrin and helps hydrate the stratum corneum; its deficiency also leads to the formation of fine wrinkles. PADI-1 ×185.61 Peptidyl Arginin Deaminase: serves in the process of formation of NMF by deaminating filaggrin. ALOX12B ×7.92 Arachidonate-12-lipoxygenase: acts upstream of ALOXE3 on the lineolate moiety of linoleyl acyl ceramides (omega- hydroxyacyl-sphingosine) to produce an epoxy-ketone derivative, a crucial step for omega-hydroxyceramides to bind to envelope proteins cornified by transglutaminases; therefore plays a crucial role in the synthesis of the lipid envelope of corneocytes and in the establishment of the skin barrier. ALOXE3 ×5.17 Hydroperoxide isomerase: acts downstream of ALOX12B; therefore plays a crucial role in the synthesis of the lipid envelope of corneocytes and in the establishment of the skin barrier. CERS3 ×2.38 Ceramide synthase 3: ceramide synthase which catalyzes the formation of ceramides in C24 and those with long acyl chains; these ceramides help to maintain the permeability of the skin and its water balance. CERS3 is known to increase during keratinocyte differentiation. ELOVL4 ×5.06 3-keto acyl-CoA synthase: catalyzes the limiting step of the 4 reactions of the long chain fatty acid elongation cycle; formation of the corneocyte lipid envelope. ABHD5 ×2.14 1-acylglycerol-3-phosphate O-acyltransferase: this enzyme plays a key role in lipid metabolism within the lamellar bodies, contributing to the formation of the skin lipid barrier. CDSN ×29.60 Corneodesmosin: presence essential for the integrity of the epidermal barrier; protein which binds the corneocytes to each other while maintaining the flexibility of the stratum corneum allowing it not to break under shocks and extensions. OCLN ×8.65 Occludin: plays an important role in the formation and regulation of the tight junction; capable of inducing adhesion when expressed in cells lacking tight junctions. TJP1 ×2.02 Tight junction protein ZO-1: structural protein connecting tight junction transmembrane proteins such as claudins and occludin to the actin cytoskeleton. CGNL1 ×26.40 Cingulin-like protein-1: involved in anchoring tight junctions to the actin cytoskeleton. CLDN4 ×10.15 Claudins: proteins present at the tight junctions that ensure CLDN7 ×7.24 cohesion between the corneocytes, via the actin network in the CLDN23 ×2.69 upper part of the epidermis; they therefore have a role of guardian of water homeostasis, preventing the evaporation of water. DEFB103B ×337.87 Human beta defensin-3: improves the barrier function via the tight junctions, by the CCR6 receptor, but also by a strong induction of claudins (see in this table), aPKC kinases, Rac1 essential in the regulation of tight junctions, and GSK3 involved in the expression of tight junction proteins. DMKN ×3.58 Dermokin: specific glycoprotein of the skin located in the upper part of the epidermis. Its experimental deficiency induces a scaly skin and fine wrinkles, as well as a disturbance of insensible water loss; the stratum corneum is weakened with in particular less ceramides present; it has been described that this protein would play a regulatory role in inflammatory dyskeratosis (ichthyosis and psoriasis).

[0121] These data show that many genes involved in epidermal differentiation and in the formation of the skin barrier are strongly stimulated by the peptide according to the invention. The peptide acts at all levels: from the metabolism of filaggrin to the production of the stratum corneum elements, the formation of lipidic lamellar bodies, and the formation of tight junctions.

[0122] The peptide of the invention thus acts favorably to guarantee the epidermis homeostasis, ensuring a good balance between the renewal by differentiation of the cells and the formation of a skin barrier of effective quality in particular regarding external aggressions. This type of activity profile guarantees good re-epithelialization of the skin tissue in subjects who have experienced an episode of acne.

[0123] Equivalent skins were prepared by first manufacturing an equivalent dermis, then once it contracted, human keratinocytes were seeded on the surface of the gel. After 14 days, equivalent skins were obtained, on which carbopol gels containing the peptide of the invention or the solvent alone were applied to their surface. After 2 days of contact, the skins were frozen to be sectioned into thin 7 μm slides and then marked in order to visualize the macrostructure of the layers. A quantification of the thickness of the stratum corneum was carried out on photos using an image software.

TABLE-US-00002 TABLE 2 Thickness of the stratum corneum quantified on photos of equivalent skins Variation (%) Control Ref 8 ppm of peptide +150%; p < 0.01 10 ppm of peptide +143%; p < 0.05

[0124] These results show the positive effect of the peptide according to the invention on epidermal differentiation. The peptide significantly increases the thickness of the stratum corneum.

[0125] 2.1.2—Epidermis Hydration and Smoothing

[0126] In addition to proteins allowing the constitution of an effective skin barrier, other proteins of the epidermis help maintain good hydration and smoothing of the skin.

[0127] Filaggrin and filaggrin-2, whose importance in the formation of the barrier has been seen, end up being modified and degraded into amino acids by the action of dedicated enzymes encoded by PRSS8, ASPRV1 and PADI-1 giving essential components of the natural moisturizing factor (NMF) found in the stratum corneum.

[0128] Hyaluronic acid, synthesized by keratinocytes, provides the epidermis with resistance to skin pressure, so that the skin protects the underlying structures. These properties are due to the unusual three-dimensional structure of hyaluronic acid, which occupies a very large volume relative to its molecular weight. By capturing water, the hyaluronic acid molecule expands and becomes perfectly resistant to compression, thus giving the epidermis elastic properties, ensuring good hydration, and contributing to a smoother skin.

[0129] Kallikreins are proteases involved in the renewal of the stratum corneum since they allow natural desquamation, thus ensuring a gentle “natural” smoothing effect. The increased expression and synthesis of these enzymes may enhance the natural process of corneocyte desquamation and be similar to a natural peel. Nevertheless, the desquamation process is managed by a balance between these proteases and their inhibitors. Therefore, it is also interesting to stimulate the expression and synthesis of natural inhibitors of these proteases, such as ELAFIN, for example, which will regulate the desquamation process.

TABLE-US-00003 TABLE 3 Variation compared to the control in the expression of genes encoding proteins involved in hydration and smoothing of the epidermis (DNA-Microarray) Expressed gene Variation Name and function of the protein FLG ×25.40 Filaggrin: serves as a substrate for the manufacture of NMF (Natural moisturizing factor) PADI1 ×185.61 Peptidyl arginin deaminase: serves in the process of formation of the NMF by deaminating filaggrin. ASPRV1 ×430.83 Skin aspartic protease cleaves profillagrin into filaggrin and helps hydrating the stratum corneum; its deficiency during aging leads to the formation of fine wrinkles. PRSS8 ×2.74 Serine protease 8: cleaves profillagrin into filaggrin and helps hydrating the stratum corneum. AQP5 ×3.11 Aquaporin 5: a small protein that forms water channels across cell membranes and provides selective water transport. KLK5 ×2.2 Kallikrein 5: serine protease involved in desquamation. PI3 ×7.73 Elafin: desquamation modulator peptide. CLDN4 ×5.48 Claudins: proteins present at the tight junctions that ensure CLDN7 ×7.24 cohesion between the corneocytes, via the actin network in CLDN23 ×2.69 the epidermis upper part; they therefore have a role of guardian of water homeostasis, preventing the evaporation of water.

[0130] These data show that in the presence of the peptide according to the invention, a large number of proteins involved in hydrating and smoothing the skin are strongly expressed.

TABLE-US-00004 TABLE 4 Variation compared to the control of the secretion of hyaluronic acid by cultured keratinocytes/effect of different concentrations of the peptide according to the invention at 72 hours of contact Pal-KTSKS concentration Variation %/non treated cells  6 ppm +33%; p < 0.01  8 ppm +42%; p < 0.01 10 ppm +62%; p < 0.01 15 ppm +107%; p < 0.01 

[0131] These data show a dose-dependent increase in the synthesis of hyaluronic acid, in the presence of the peptide according to the invention.

[0132] 2.1.3—Antimicrobial Action and Skin Immunity

[0133] To protect against pathogenic bacteria or bacteria which may lead to undesirable effects, for example Propionibacterium acnes (the acne bacteria) or against yeasts of the Malassezia genus (which causes dandruff), keratinocytes synthesize antimicrobial peptides (AMPs); defensins, cathelicidins, S100 proteins and PI3 are examples of these. By their targeted action against microorganisms harmful to the skin, antimicrobial peptides will protect and strengthen the skin microbiota.

[0134] These peptides are important effectors of the “chemical barrier” put in place to protect the skin from infection and the resulting inflammation.

[0135] In addition, these peptides act by modulating innate immune responses, to obtain protection against infection, control of inflammation and scarring, and initiate adaptive immune responses. The human beta-defensin-3 (HBD3) for example is an antimicrobial peptide which intervenes at several levels. It is a key molecule in the skin's immune system, a marker of immune barrier function in the skin. In particular, it has a broad spectrum of destruction against gram+ and gram− bacteria and yeasts. Stimulating the expression of this peptide is of great interest in cosmetics, on the one hand in the prevention and treatment of acne (against the Propionibacterium acnes bacterium) and, on the other hand, in the treatment of a dandruff condition. (against yeasts of the genus Malassezia).

TABLE-US-00005 TABLE 5 Variation compared to the control in the expression of genes encoding proteins involved in antimicrobial defense (DNA-Microarray) Expressed gene Variation Name and function of the protein DEFB103B ×337.87 Human beta defensin-3: broad spectrum antimicrobial peptide RNASE7 ×40.85 RNase 7: exhibits abroad spectrum of antimicrobial activity; one of the most powerful and effective human antimicrobial proteins known. PI3 ×7.73 Elafin: antimicrobial peptide. S100A7 ×15.73 Psoriasin: participates in innate immune defense against pathogens on the surface of the skin. DEFB1 ×4.48 Beta-1-defensin: antimicrobial peptide. LCE3A ×306.86 Late Cornified Envelop Proteins: these are the last components LCE3B ×324.01 to be bridged during the maturation phase in the stratum corneum. LCE3D ×1454.67 They are also reported to have a role in antimicrobial defense. LCE3E ×612.9 LCE2C ×37.7 HMOX1 ×29.27 Heme Oxygenase-1: inducible antioxidant enzyme, cytoprotective essential to minimize the effects of oxidative stress in connection with NRF2 and Keap1 and against bacteria and other microorganisms.

[0136] These data show that in the presence of the peptide according to the invention, a large number of proteins involved in antimicrobial defense are strongly expressed.

TABLE-US-00006 TABLE 6 Growth of the P. acnes bacterium: time required to reach an OD of 1 in the control case and in the presence of the peptide according to the invention (N = 3 independent experiments; n = 2 cultures per case) 6 ppm of 9 ppm of 12 ppm of Case Control peptide peptide peptide Time in hours 26 54 103 135

[0137] These data show that the peptide according to the invention strongly and dose-dependently inhibits the growth of P. acnes.

[0138] This study was also carried out to follow the persistent effect of the peptide according to the invention on P. acnes, and to see if the inhibition can be quickly lifted in the absence of the peptide. The peptide was brought into contact with the cells from the start, as before. After 48 hours of contact and evaluation of the quantity of cells, the cells of all the cases were centrifuged and returned to a fresh medium without solvent or peptide, all the cases having the same quantity of cells. The growth was then assessed again.

[0139] As a result, it is observed that the peptide does exert a net effect on the slowing down of growth when it is in the presence of P. acnes and once removed, the cells regain a growth potential identical to what is observed for the control cases. The peptide therefore exhibits an inhibitory effect when in contact with P. acnes and has no persistent effect.

[0140] The effect of the peptide on the inhibition of adhesion and biofilm formation of P. acnes was also studied.

[0141] When the bacteria growth, they accumulate, and when a bacteria aggregate reaches a sufficient quorum, namely a sufficient cell quantity, a cell behavior change is observed. More intercellular communications between the cells is possible, and the cells modify their physiology, leading to harmful effects for the host, in particular via the production of a protective biofilm. This phenomenon is called “quorum sensing”.

[0142] Avoiding the formation of these biofilms by reducing the growth of the germ, or dissociating these biofilms already formed has the advantage of limiting the quorum effect and reducing the pre-inflammatory consequences on the cells of the follicle.

[0143] The adhesion of 106 CFU/mL of P. acnes (strain ATCC6919) to a surface for 72 hours in an appropriate medium was evaluated. At the end of the contact plus more or less the peptide, the quantity of isolated cells, not attached, was estimated by an OD at 600 nm.

[0144] The biofilm and the bacteria still attached were labeled with crystal violet solution for 20 min. After rinsing, the quantity of crystal violet remaining on the biofilms was assayed, after extraction, also with a measurement of OD at 600 nm.

[0145] The results of this study show that in the control cases the bacteria adhere well to the support as a function of time. The OD600 nm goes from 0.0102 to 0.1515, or 14.8 times more than at TO. The peptide can greatly reduce the adhesion of the bacteria at 48 hours and 72 hours, a drop in adhesion of more than 83% is achieved in two concentrations tested. By discouraging the adhesion of P. acnes, the peptide reduces its possibilities of reaching its quorum, this completes the spectrum of action of the peptide according to the invention on P. acnes which has also shown its ability to inhibit its multiplication.

[0146] Regarding the formation of the biofilm, it is observed that, in the control case, the biofilm develops from 0.02 units of OD600 nm (24 hours) to 2.7 units, ie 135 times more in 3 days. Contact with the peptide almost completely prevents the formation of the biofilm by P. acnes ((respectively −98% for 6 ppm and −99% for 12 ppm, both p<0.01). By preventing the biofilm formation, the peptide reduces the possibilities of P. acnes to reach a quorum.

[0147] The effect of the peptide on the biofilm stability was also evaluated, the peptide being only added 24 hours after the start of the P. acnes culture.

[0148] The results show that the biofilm struggles to exist under these conditions. At 72 hours, the biofilm formed, in the control case, is at 1,861 OD600 nm units, a value reduced from 89% to 93% (the two p<0.01 vs the control) for 6 ppm and 12 ppm of peptide respectively. By reducing the stability of the biofilm, therefore reduces the possibilities of P. acnes to reach its quorum.

[0149] The lipase activity, ie the ability of P. acnes to metabolize certain lipids supplied by sebum, is also one of the criteria for the birth of the virulence of P. acnes. This has also been tested.

[0150] A culture of P. acnes was carried out. The cells were then separated from the culture medium containing the lipases excreted by P. acnes. The peptide of the invention was added to samples of this cell-free medium and lipase activity was monitored using a fluorescent 4-methylumbelliferyl oleate (4-MUO) probe which is converted by lipases to fluorescent 4-methylumbelliferone, and whose signal has been recorded.

TABLE-US-00007 TABLE 7 Reduction in lipase activity of P. acnes, effect of the invention peptide, n = 6. The means are in relative fluorescence units 6 ppm of 9 ppm of 12 ppm of Solvent control peptide peptide peptide Variation (%) Reference −22%; p < 0.01 −64%; p < 0.01 −88%; p < 0.01

[0151] The results show that the peptide exhibits a dose-dependent inhibitory effect on the activity of the extracellular lipases of P. acnes.

[0152] It is also interesting to mention that the peptide according to the invention is selective towards P. acnes. The following test on S. epidermidis was carried out for this purpose. S. epidermidis is one of the most common commensal germs on skin. It serves as a repellent, in particular for pathogenic S. aureus, and is said to control the excessive expansion of P. acnes. It is therefore interesting to see that the peptide according to the invention depresses the growth of this germ, which would otherwise indicate a lack of selectivity and the risk of dysbiosis.

[0153] S. epidermidis was inoculated in an appropriate medium and its growth was followed over time. The peptide according to the invention (6 ppm and 12 ppm) was tested on these cells for 48 hours in comparison with the control case (n=6).

[0154] The results showed that the growth of S. epidermidis proceeds as expected in the control case. At the same time, the peptide of the invention only induces a slight, temporary slowdown in growth relative to control.

[0155] An in vivo study on 30 volunteers conforted these results by showing that the peptide according to the invention did not vary S. epidermidis neither over time (28 days) with the cream according to the invention nor compared to placebo.

TABLE-US-00008 TABLE 8 Effect of Propionibacterium acnes on keratinocyte migration. Variation compared to the control of keratinocyte migration in the presence of Propionibacterium acnes (N = 3 independent experiments, n = 2 cultures per case) 5 ppm of 7 ppm of Case Control peptide peptide Without P. acnes Reference 1 −3% (nsd) −0.36% (nsd) With P. acnes +106.4 Reference 2 −49.67% −66.15% (p < 0.01) (p < 0.01)

[0156] These data show that the acne bacteria strongly promote the migration of keratinocytes (+106.4%), as described in the scientific literature. In the absence of Propionibacterium acnes, the peptide according to the invention has no effect on the migration of keratinocytes. In the presence of Propionibacterium acnes, the peptide according to the invention slows down the migration of keratinocytes in a dose-dependent and significant manner. As a result, it will slow down the development of acne and reduce its severity.

[0157] 2.1.4—Detoxifying Action

TABLE-US-00009 TABLE 9 Variation compared to the control of the gene expression encoding proteins involved in the detoxification of the epidermis (DNA-Microarray) Expressed gene Variation Name and function of the protein HMOX1 ×29.27 Heme Oxygenase 1: antioxidant enzyme, cytoprotective against the effects of oxidative stress.

[0158] These data show that the peptide according to the invention strongly stimulates the Heme Oxygenase 1 enzyme which acts in the defense against oxidation (protection against reactive oxygen species).

[0159] 2.1.5—Action Intended to Reduce the Deleterious Effects of Inflammation

[0160] Recently, it appeared that antimicrobial defense peptides had a broader action in the skin and that they also had a role in cell proliferation, migration, and differentiation, in the regulation of inflammatory responses by controlling the production of different cytokines, in the development of wound healing in the epidermis and in the improvement of the barrier function. This is particularly the case with human beta defensin-3. It is further described as involved in skin immunity via the production of various cytokines/chemochines. Furthermore, it is also described to counteract the inflammatory effects of bacterial lipopolysaccharide. Finally, it has a feedback control of inflammatory activity by inhibiting the TLRs (Toll Like receptor) pathway.

[0161] The skin is subjected to constant stress (exposure to UV rays, smoke, pollutants, etc.) some of which provoke a direct or indirect inflammatory response. The uncontrolled or constant inflammatory response, although of low intensity, results in the production of cytokines such as IL-1α, IL-1β, IL-6, TNF α, and active lipids such as PGE2 intended to attract or stimulate the production of a pro-inflammatory secretome from other cells, causing cascade reactions. The pro-inflammatory microenvironment thus formed leads to modifying the skin homeostasis and gradually leads to the modification or even destruction of the biomolecules of cells and tissues. It also leads to the disruption of the integrity of the skin barrier. Thus, the mediators of inflammation, IL-6 and PGE-2, are known to induce, via micro-inflammations, the phenomena of premature aging. In addition, sensitive and irritated skin is characterized by an abnormally high secretion of cytokines, pro-inflammatory peptides (IL-1, IL-6 for example) and pro-inflammatory lipids (PGE-2 for example).

TABLE-US-00010 TABLE 10 Variation compared to the control in the expression of genes encoding proteins involved in the protection of the skin against inflammatory phenomena (DNA-Micoarray) Expressed gene Variation Name and function of the protein DEFB103B ×337.87 Human beta defensin-3: see its action above. IL37 ×7.82 Interleukin-37: anti-inflammatory cytokine, suppresses or reduces the production of pro-inflammatory cytokines, including IL1α and IL6; known to suppress keloid fibroblasts; inhibits NF-κB and mitogen activation protein kinase; “Therapeutic cytokine” against inflammatory disorders including psoriasis. SPINK5 ×3.77 Serine protease inhibitor Kazal-type 5: serine protease inhibitor, important for anti-inflammatory protection of the skin; contributes to the integrity and barrier function of the skin by regulating the activity of proteases involved in the desquamation and defense of the skin. HMOX1 ×29.27 Heme Oxygenase-1: strong anti-inflammatory activity, in particular by its action against bacterial lipopolysaccharide. PRSS8 ×2.74 Serine protease-8: works by reducing the pro-inflammatory phenomena associated with TLR4, the activation of which leads to an intracellular NFB signaling pathway and the production of inflammatory cytokines. TIMP1 ×3.68 Metallopeptidase inhibitor 1: inhibitor of metalloproteases, thus limits the degradation of collagen. TIMP2 ×5.96 Metallopeptidase inhibitor 2: inhibitor of metalloproteases, thus limits the degradation of collagen. ANXA1 ×3.05 Annexin A1: has anti-inflammatory activity. It binds to membrane phospholipids, contributing to their repair. Inhibits the formation of PGE2 and the activation of NFκB. LCE3A ×306.86 Late Cornified Envelop 3A: plays a positive role against inflammation.

[0162] These data show an activity against inflammation through the overexpression of various genes, including that encoding the cytokine IL-37, that encoding human beta-defensin 3 and that encoding annexin A1. Thus, the peptide according to the invention, incorporated into a cosmetic composition, being capable of strongly stimulating the gene expression of human beta defensin 3, an integral part of the innate immune system, will have a defensive action to prevent the penetration or the proliferation of infectious agents in the skin and the resulting inflammation. This is reinforced by the results of ELISA tests described below showing a decrease in production of two markers of inflammation in the human keratinocyte: basal for PGE2, after UVB exposure for PGE2 and IL6.

TABLE-US-00011 TABLE 11 Variation compared to the control of the secretome of pro-inflammatory mediators by NHKs exposed to UVB (by immune-enzymatic assay) Marker 3 ppm 10 ppm 15 ppm IL6 −4% (nsd) −33% (p < 0.01) −65% (p < 0.01) PGE2 +1% (nsd) −41% (p < 0.01) −63% (p < 0.01) nsd: non significative

[0163] These data show the very interesting effect of the peptide according to the invention to moderate the secretion of pro-inflammatory mediators by NHKs which have been exposed to UVB irradiation. This effect is particularly interesting for sensitive skin irritated by exposure to radiation and various pollutants that cause micro-inflammation.

[0164] The preferred peptide according to the invention improves the cutaneous defense system against bacteria, oxidants, and radiation by modulating the inflammatory phenomena which result from these toxic agents. All the presented markers act in this direction.

[0165] 2.2—Action on the Dermal Extracellular Matrix and on the Basement Membrane

[0166] In addition, advantageously, the tests given below show that the peptide according to the invention also exhibits a complementary activity on the dermal tissue and its essential matrix components (collagens, elastin, fibronectin).

[0167] The dermis of an 80-year-old has four times more fragmented collagen than that of people 20-30 years of age who have longer fibers. This fragmentation leads to a reduction of up to 80% of the interactions that cells have with their matrix. With age, dermal fibroblasts produce less supportive protein, including less collagen I, the most abundant protein in the skin, and less elastin. This explains the structural and functional decline of the skin, which becomes less dense, less organized, and less dynamic. The weakening of the qualities of the support tissue causes a decrease in the visco-elastic characteristics of the skin: firmness, elasticity and tone are thus reduced by about 13% per decade.

[0168] Collagen 4 is the most important building block of the basement membrane. This membrane provides the junction and separation between the dermis and the epidermis (it is also called the dermo-epidermal junction or DEJ).

TABLE-US-00012 TABLE 12 Variation in the production of the C terminal peptide of pro- collagen-I, collagen-I, collagen-IV, fibronectin in the presence of the preferred peptide according to the invention: Terminal C peptide of pro- collagen I Collagen I Collagen IV Fibronectin variation %/ Variation %/ Variation %/ Variation %/ Concentrations control control control control Control Reference Reference Reference Reference  8 ppm +61%; p < 0.01  +75%; p < 0.01 +18%; p < 0.01 +40%; p < 0.01 10 ppm +94%; p < 0.01 +184%; p < 0.01 +98%; p < 0.01 +67%; p < 0.01

[0169] The MMPs (dermal matrix proteases) are naturally controlled in tissues by their inhibitors TIMPs (tissue inhibitors of dermal matrix proteases) which prevents blind enzymatic degradation activity. It is the balance of TIMP versus MMP that determines the level of activity of the latter. TIMPs are small glycoproteins whose production is associated with the reduction of chronic pathologies linked to MMPs and a reduction in photo-damage linked to UV rays. By combining with MMPs, TIMPs neutralize them and therefore limit the fragmentation of the dermal matrix, which thus preserves its elasticity and firmness.

TABLE-US-00013 TABLE 13 Variation compared to the control in the expression of genes encoding TIMPs involved in the protection of the dermis (DNA-Microarray) Expressed gene Variation Name and function of the protein TIMP1 ×3.68 Metallopeptidase inhibitor 1: metalloprotease inhibitor, thus limiting collagen degradation. TIMP2 ×5.96 Metallopeptidase inhibitor 2: metalloprotease inhibitor, thus limiting collagen degradation.

[0170] These data show that the peptide according to the invention can, in addition to its activity on the epidermis, strengthen the dermis and the basement membrane, for more skin firmness and elasticity.

[0171] 2.3—Beneficial Action on Nails and Hair

[0172] 2.3.1—on Nails

[0173] Filaggrin and trichohyalin coexist with keratins 6 and 16 in the nail bed. These are constituent proteins. Filaggrin and trichohyalin may act to stabilize the network of intermediate filaments of K6 and K16.

TABLE-US-00014 TABLE 14 Variation compared to the control in the expression of genes encoding constituent proteins of the nail or involved in its formation (DNA-Microarray) Expressed gene Variation Name and function of the protein TCHH x 2.39 Trichohyalin: present in the nail bed FLG x 25.40  Filaggrin: also present in the nail bed PPL x 4.12 Periplakin: serves as a link between the desmosome and the horny envelope; interacts with the intermediate filaments; confers mechanical resistance to nail-like hard epithelia.

[0174] These data show that two constituent compounds of the nail and a compound involved in its formation or retention have their gene expression increased following contact with the peptide according to the invention.

[0175] The compound according to the invention thus appears to be perfectly indicated for the maintenance of healthy nails or the treatment of damaged nails.

[0176] 2.3.2—on Hair (Comprising Eyelashes and Eyebrows)

[0177] Trichohyalin is expressed in specific epithelia, exceptionally strong mechanically, such as cells in the inner sheath of the hair follicle. It is subjected to modifications by enzymes, in particular transglutaminases, which introduce intra- and inter-proteic crosslinks. It is a reticulated multifunctional protein that functions in the hair's inner root sheath, imparting and coordinating mechanical strength between the peripheral cell envelope structures and the cytoplasmic keratin filament network (intermediate filaments).

TABLE-US-00015 TABLE 15 Variation compared to the control in the expression of genes coding for constitutive proteins of the hair or involved in its formation (DNA-Microarray) Expressed gene Variation Name and function of the protein TCHH x 2.39 Trichohyalin: present in the inner sheath of the hair follicle. CDSN x 29.60  Corneodesmosin: essential presence for the epidermal barrier integrity; protein which binds firmly the corneocytes to each other while maintaining the flexibility of the stratum corneum which prevents it from breaking under shocks and extensions. The absence of corneodesmosin leads to thinning of the hair and their loss. ASPRV1 x 430 Skin aspartic protease: present in the inner sheath of the hair follicle; cleaves profillagrin into filaggrin. ALOX12B x 7.92 Arachidonate 12-lipoxygenase: acts upstream of ALOXE3 on the lineolate moiety of linoleyl acyl ceramides (omega- hydroxyacyl-sphingosine) to produce an epoxy-ketone derivative, a crucial step for omega-hydroxyceramides to bind to keratin-associated proteins (KAPs) thanks to transglutaminases; therefore, plays a crucial role in the synthesis of the cell lipid envelope of the root sheath of the follicle. ALOXE3 x 5.17 Hydroperoxide isomerase: acts downstream of ALOX12B; therefore plays a crucial role in the synthesis of the cell lipid envelope of the root sheath of the follicle. TGM3 x 132 Transglutaminase 3: is expressed in the hair shaft; participates in the progressive scaffolding of the hair shaft by creating bonds between the intermediate filaments and to the proteins associated with keratin (KAPs); thus, contributes to the physical resistance of the hair structure. PPL x 4.12 Periplakin: serves as a link between the desmosome and the hair follicle; interacts with the intermediate filaments; confers mechanical resistance to hard epithelia such as the inner sheath of the hair follicle.

[0178] These data show that a certain number of compounds of the hair itself and of compounds involved in its formation or maintenance have their gene expression increased following contact with the peptide according to the invention. The compound according to the invention thus appears to be perfectly indicated for action in the capilar field to regulate hair growth, improve quality and appearance, correct defects.

[0179] II—on Other Preferred Peptides of the Invention: The Pal-KTSKT (SEQ ID No 7), the Pal-GKTSKS (SEQ ID No 6) and the Pal-KTSKSA (SEQ ID No 8)

[0180] 1—P. acnes growth curve (same protocol as described above at point 1.4)

[0181] P. acnes is thawed and grown over 3 days in M20 media. Then, optical density at 600 nm (OD600) is measured and 2×106 CFU*/mL are plated in well plates. P. acnes is then treated with 6 ppm, 9 ppm and 12 ppm of peptides. To follow bacterial cell multiplication, OD600 is measured regularly for about 1 week. These data are used to generate P. acnes growth curve and to estimate the effect of the peptides of the invention on C. acnes. Each result is a mean obtained from 6 replicates (n=6) and a standard deviation of the mean (sdm) is obtained from these results. Statistical evaluations are performed on results using a Student t test. Two independent experiments are performed (N=2). The time needed for P. acnes to reach 0.5 of OD at 600 nm after treatment with each peptide is shown in the table below.

TABLE-US-00016 TABLE 16 Peptide of the Time (in hour) to reach OD.sub.600 nm = 0.5 +/−sdm invention Vehicle Control 6 ppm 9 ppm 12 ppm Pal-KTSKS-OH 43.9 h 48.8 h** 55.0 h** 87.3 h** +/−0.73 +/−1.07 +/−0.31 +/−1.69 Pal-GKTSKS-OH 43.9 h 45.6 h*  56.2 h** 70.2 h** +/−0.73 +/−1.27 +/−0.54 +/−1.70 Pal-KTSKSA-OH 42.4 h 47.3 h** 57.9 h** 60.5 h** +/−0.46 +/−0.68 +/−0.55 +/−0.59 Pal-KTSKT-OH 42.4 h 47.7 h** 55.2 h** 85.1 h** +/−0.46 +/−0.88 +/−0.6 +/−2.13 *p < 0.05 or **p < 0.01 vs vehicle

[0182] The results show that vehicle required 42-44 h for reaching an OD.sub.600nm of 0.5.

[0183] These results confirm the results given before on the Pal-KTSKS: the peptide triggers a delay in P. acnes growth versus vehicle whatever the concentration used; this effect is dose-dependent of the concentrations (for 6 ppm, 9 ppm and 12 ppm: +5 h, +11 h and +43 h respectively).

[0184] The Pal-GKTSK triggers a delay in P. acnes growth versus vehicle; this effect is dose-dependent of the concentration (for 6 ppm, 9 ppm and 12 ppm: +2 h, +12 h and +26 h respectively).

[0185] The Pal-KTSKSA triggers a delay in P. acnes growth versus vehicle; this effect is dose-dependent of the concentration (for 6 ppm, 9 ppm and 12 ppm: +5 h, +15 h and +18 h respectively).

[0186] The Pal-KTSKT triggersa delay in P. acnes growth versus vehicle; this effect is dose-dependent of the concentration (for 6 ppm, 9 ppm and 12 ppm: +5 h, +13 h and +43 h respectively).

[0187] 2—Keratinocyte Differentiation

[0188] Normal human keratinocytes (NHK) are grown on wells plate. When subconfluence was reached, cells received various concentrations of the peptides. After few days, evaluation of differentiation is compared to solvent control under microscope and cells are fixed to allow the study of involucrin by immunohistochemistry.

[0189] The below table summarizes a visual evaluation of keratinocytes differentiation.

TABLE-US-00017 TABLE 17 Visual evaluation of NHK differentiation Day 2 Day 4 Pal-KTSKS + ++ Pal-KTSKSA + ++ Pal-KTSKT + ++

[0190] Results on the Pal-KTSKS are confirmed: the peptide strongly increases keratinocytes differentiation both at day 2 and day 4 after contact.

[0191] The results show that the Pal-KTSKSA induces keratinocytes differentiation after 2 and 4 days in a similar way than the Pal-KTSKS.

[0192] The results show a similar induction of keratinocytes differentiation of the Pal-KTSKT compared to Pal-KTSKS.

[0193] 3—Involucrin Quantification

[0194] Involucrin is an early marker of keratinocytes differentiation. The below table show the percentage of variation of involucrin vs. Control.

TABLE-US-00018 TABLE 18 Involucrin (% var vs. Control); t.test Control — Ref Pal-KTSKS 5 ppm +177%; p < 0.01 Pal-KTSKSA 5 ppm +152%; p < 0.01 Pal-KTSKT 5 ppm +125%; p < 0.01

[0195] These results confirm the induction of keratinocytes differentiation for the three peptides according to the invention: the Pal-KTSKS, the Pal-KTSKSA, and the Pal-KTSKT.

[0196] D—Galenic/Preparation of a Composition According to the Invention for an End User

[0197] The peptide(s) according to the invention can be formulated with additional active cosmetic ingredients, coming if required in support and/or in complement of activity, either in the ingredient form, or at the time of the realization of the final cosmetic composition for the end consumer. This composition can be applied to the face, body, neckline, scalp, hair (from scalp and body, comprising eyelashes and eyebrows), in any form or vehicles known to those skilled in the art, in particular in the form of solution, dispersion, emulsion, paste or powder, individually or as a premix or be vehiculed individually or as a premix.

[0198] In cosmetics, applications can be offered in particular in the skin care ranges for the face, body, hair (from scalp and body comprising eyelasches and eyebrows) and in make-up-care ranges. These ingredients can be of any category according to their role(s), the place of application (body, face, neck, bust, hands, hair, etc.), the desired final effect and the targeted consumer, for example antioxidant, tensor, moisturizer, nourishing, protective, smoothing, remodeling, volumizing (lipofiling), acting on the radiance of the complexion, acting on spots, under eye dark circles and bags, anti-glycation, anti-aging, anti-wrinkle, slimming, soothing, myo-relaxing, anti-redness, anti-stretch marks, sunscreen, etc.

[0199] The Personal Care Products Council (International cosmetic ingredient dictionary & handbook (20th Ed. 2020) published by “the Cosmetic, Toiletry, and Fragrance Association, Inc.”, Washington, D.C.) describes a wide variety, without limitation, of cosmetic ingredients usually used in the skincare and scalp care industry, which are suitable for use as additional ingredients in the compositions of the present invention.

[0200] In particular, mention may be made of at least one of the compounds chosen from compounds of vitamin B3, compounds such as niacinamide or tocopherol, retinoid compounds such as retinol, hexamidine, α-lipoic acid, resveratrol or DHEA, hyaluronic acid, peptides, in particular N-acetyl-Tyr-Arg-O-hexadecyl ester, Pal-KTTKS (SEQ ID No 1), Pal-VGVAPG (SEQ ID No 3), Pal-KTFK (SEQ ID No 9), Pal-GHK, Pal-KMO.sub.2K (MO.sub.2 corresponding to a methionine sulfone), Pal-GQPR (SEQ ID No 2) and Pal-K(P)HG (K(P) corresponding to a proline grafted on the lysine), which are classic active ingredients used in topical compositions cosmetics or dermo-pharmaceuticals. Other additional skin care actives that are particularly useful can be found in Sederma's and Crodarom's commercial literature and at www.croda.com.

[0201] In activity reinforcing on the properties of epidermis and/or stratum corneum, the additional active agent can be chosen from the group comprising: phospholipids, various ceramides, sphingosine, phytosphingosine, glycosphingolipids, cholesterol and its derivatives, sterols (in particular those of canola and soybean), fatty acids (in particular linoleic acid, palmitic acid, lipoic acid and thioctic acid), squalane (in particular from olives), triglycerides (in particular coconut oil), lanolin, lanolin alcohols, lanosterol, vitamin D3, tocopheryl nicotinate, various oils (in particular, argan, rose, and baobab), ascorbic acid, N-acetyl cysteine and N-acetyl-L-serine, vitamin B3 compounds (such as niacinamide and nicotinic acid), panthenol, pseudofilaggrine, arginine, serine, salts of PCA (pyrrolidone carboxylic acid), an extract of Centella asiatica leaf (titrated in madecassoside and asiaticoside), certain extracts of plants (wild yam roots, chestnut, cedar bud and solanaceae), plankton and yeast.

[0202] Mention may also be made of the actives marketed by Sederma: Venuceane™ (extract of Thermus thermophilus fermentation medium), Moist 24™ (hydroglycolic extract of Imperata cylindrica root), Dermaxyl™ (combination of ceramide 2 and the Pal-VGVAPG peptide), Senestem™ (a Plantago lanceolata cell culture extract), Ceramide 2™ (ceramide), Ceramide HO3™ (hydroxyceramide), Optim Hyal™ (acetylated glucuronic acid oligosaccharides), Meiritage™ (combination of root extracts of Bupleurum falcatum, Astragalus membranaceus and Atractylodes macrocephala) Revidrat™ (myristyl phosphomalate), Pacifeel™ (a Mirabilis jalapa plant extract), Hydronesis™ (fermentation of Salinococcus hispanicus), Shea unsaponifiable NG™, Citystem™ (a cell culture extract ofMarrubium vulgare) and the Pal-KTFK peptide, in particular in its vehiculed form in the commercial product Crystalide™.

[0203] In general, the following commercial actives may also be mentioned by way of example: betain, glycerol, Actimoist Bio 2™ (Active organics), AquaCacteen™ (Mibelle AG Cosmetics), Aquaphyline™ (Silab), AquaregulK™ (Solabia), Carciline™ (Greentech), Codiavelane™ (Biotech Marine), Dermaflux™ (Arch Chemicals, Inc), Hydra′Flow™ (Sochibo), Hydromoist L™ (Symrise), RenovHyal™ (Soliance), Seamoss™ (Biotech Marine), Argireline™ (trade name for acetyl hexapeptide-3 of Lipotec), le spilanthol or an extract of Acmella oleracea known under the trade name Gatuline Expression™, an extract of Boswellia serrata under the trade name Boswellin™, Deepaline PVB™ (Seppic), Syn-AKE™ (Pentapharm), Ameliox™, Bioxilift™ (Silab), PhytoCellTec™Argan (Mibelle), Papilactyl D™ (Silab), Preventhelia™ (Lipotec), or one or more active ingredient following sold by Sederma: Subliskin™, Venuceane™, Moist 24™, Vegesome Moist 24™, Essenskin™ Juvinity™, Revidrat™, Resistem™, Chronodyn™, Kombuchka™, Chromocare™, Calmosensine™ Glycokin factor S™, Biobustyl™, Idealift™, Ceramide 2™, Ceramide A2™, Ceramide HO3™ Legance™, Intenslim™, Prodizia™, Beautifeye™, Pacifeel™, Zingerslim™, Meiritage™, Sebuless™, Apiscalp™, Rubistem™, Citystem™, Neonyca™, NG Shea Unsaponifiable™ Majestem™, Hydronesis™, Poretect™, Amberstem™, Synchrolife™, Feminage™, or mixture thereof. Among plant extracts (in the form of classical plant extracts or prepared by an in vitro process) can be used as additional actives, there may more particularly be mentioned extracts of ivy, for example English Ivy (Hedera helix), of Bupleurum chinensis, of Bupleurum falcatum, of arnica (Arnica montana L), of rosemary (Rosmarinus officinalis N), of marigold (Calendula officinalis), of sage (Salvia officinalis L), of ginseng (Panax ginseng), of gingko biloba, of St.-John's-Wort (Hyperycum perforatum), of butcher's-broom (Ruscus aculeatus L), of European meadowsweet (Filipendula ulmaria L), of big-flowered Jarva tea (Orthosiphon stamincus benth), of artichoke (Cynara scolymus), of algae (Fucus vesiculosus), of birch (Betula alba), of green tea, of cola nuts (Cola nipida), of horse-chestnut, of bamboo, of Centella asiatica, of heather, of fucus, of willow, of mouse-ear, of escine, of cangzhu, of Chrysanthellum indicum, of the plants of the Armeniacea genus, Atractylodis platicodon, Sinnomenum, pharbitidis, Flemingia, Coleus comme C. forskohlii, C. blumei, C. esquirolii, C. scutellaroides, C. xanthantus and C. barbatus, such as the extract of root of Coleus barbatus, extracts of Ballote, of Guioa, of Davallia, of Terminalia, of Barringtonia, of Trema, of Antirobia, Cecropia, Argania, Dioscoreae such as Dioscorea opposita or Mexican, extracts of Ammi visnaga, of Siegesbeckia, in particular Siegesbeckia orientalis, vegetable extracts of the family of Ericaceae, in particular bilberry extracts (Vaccinium angustifollium) or Arctostaphylos uva ursi, aloe vera, plant containing sterols (e.g., phytosterol), Manjistha (extracted from plants of the genus Rubia, particularly Rubia cordifolia), and Guggal (extracted from plants of the genus Commiphora, particularly Commiphora mukul), kola extract, chamomile, red clover extract, Piper methysticum extract (Kava Kava™ from Sederma), Bacopa monieri extract (Bacocalmine™ from Sederma) and sea whip extract, extracts of Glycyrrhiza glabra, of mulberry, of melaleuca (tea tree), of Larrea divaricata, of Rabdosia rubescens, of Euglena gracilis, of Fibraurea recisa Hirudinea, of Chaparral Sorghum, of sun flower extract, of Enantia chlorantha, of Mitracarpe of Spermacocea genus, of Buchu barosma, of Law sonia inermis L., of Adiantium capillus-veneris L., of Chelidonium majus, of Luffa cylindrica, of “Japanese Mandan” (Citrus reticulata Blanco var. unshiu), of Camelia sinensis, ofImperata cylindrica, of Glaucium Flavum, of Cupressus sempervirens, of Polygonatum multi/Thrum, of Loveyly hemsleya, of Sambucus nigra, of Phaseolus lunatus, of Centaurium, of Macrocystis pyrifera, of Turnera diffusa, of Anemarrhena asphodeloides, of Portulaca pilosa, of Humulus lupulus, of Coffea arabica, of Rex paraguariensis, or of Globularia cordifolia, of Oxydendron arboretum, ofAlbizzia julibrissin, of Zingimber zerumbet smith, of Astragalus membranaceus, of Atractylodes macrocephalae, of Plantago lanceolata, of lentopodium alpinum (or edelweiss), of Mirabilis jalapa, of Apium graveolens, of Marrubium vulgare, Buddleja davidii Franch, Syringa vulgaris or orchids.

[0204] The compositions of the present invention may include other peptides, including, without limitation, di-, tri-, tetra-, penta-and hexapeptides and their derivatives. According to a particular embodiment, the concentration of the additional peptide(s), in the composition, ranges from 1×10.sup.−7% and 20%, preferably from 1×10.sup.−6% and 10%, preferably between 1×10.sup.−5% and 5% by weight. The term “peptide” refers here to peptides containing 10 amino acids or less, their derivatives, isomers and complexes with other species such as a metal ion (e.g. copper, zinc, manganese, magnesium, and others). The term “peptides” refers to both natural peptides and (bio)synthetic peptides. It also refers to compositions that contain peptides and which are found in nature, and/or are commercially available.

[0205] Suitable dipeptides for use herein include but are not limited to Carnosine (βAH), YR, VW, NF, DF, KT, KC, CK, KP, KK, TT, PA, PM or PP.

[0206] Suitable tripeptides for use herein include, but are not limited to RKR, HGG, GKH, GHK, GGH, GHG, KGH, KHG, KFK, KAvaK, KβAK, KAbuK, KAcaK, KPK, KMOK, KMO.sub.2K (MO.sub.2 being a di-oxygenated sulfoxide methionine), KVK, PPL, PPR, SPR, QPA, LPA, SPA, K(Ac)HG or K(Ac)GH, K(Ac) being a lysine with the amine function of the lateral chain acetylated, as disclosed in WO2017/216177, K(P)HG or K(P)GH, K(P) being a lysine with its lateral chain grafted with a proline, K(Pyr)HG or K(Pyr)GH, K(Pyr) being a lysine with its lateral chain grafted with a pyroglutamic acid, K(Hyp)HG or K(Hyp)GH, K(Hyp) being a lysine with its lateral chain grafted with a hydroxyproline, as disclosed in WO2016/097965.

[0207] Suitable tetrapeptides for use as additional peptides herein include but are not limited to GQPR (SEQ ID No 10), RSRK (SEQ ID No 11), KTFK (SEQ ID No 12), KTAK (SEQ ID No 13), KAYK (SEQ ID No 14), KFYK (SEQ ID No 15), or TKPR (SEQ ID No 16).

[0208] A suitable non limitative example of pentapeptide is the KTTKS (SEQ ID No 17), and suitable examples of hexapeptides are the GKTTKS (SEQ ID No 18) and VGVAPG (SEQ ID No 19).

[0209] Other suitable peptides for use according to the present invention can be selected, this list being not limitative, from: lipophilic derivatives of peptides, preferably palmitoyl (Pal) derivatives or myristoyl (Myr), and metal complexes as aforementioned (e.g. copper complex of the tripeptide HGG or GHK).

[0210] Preferred dipeptides include for example N-Palmitoyl-β-Ala-His, N-Acetyl-Tyr-Arg-hexadecylester (Calmosensine™, Idealift™ from Sederma), Pal-RT or Pal-KT (from Sederma). Preferred tripeptide derivatives include for example Pal-GKH and Pal-GHKou N-Biot GHK (from Sederma), the copper derivative of HGG (Lamin™ from Sigma), Lipospondin (N-Elaidoyl-KFK) and its analogs of conservative substitution, N-Acetyl-RKR—NH.sub.2 (Peptide CK+), N-Biot-GHK (from Sederma), Pal-KAvaK, Pal-KβAlaK, Pal-KAbuK, Pal-KAcaK, or Pal-KMO.sub.2K (Matrixyl®synthe′6® from Sederma), Pal-KVK (Syn-Coll™ of DSM), and derivatives thereof. Mention may also be made here of the anti-aging tripeptides of general Formula X-Pro*-Pro*-Xaa-Y described in WO2015181688 application with Xaa selected from Leu, Arg, Lys, Ala, Ser, and Asp, at the N-terminus, X chosen from H, —CO—R.sup.1 and —SO.sub.2-R.sup.1 and at the C-terminal end Y chosen from OH, OR.sup.1, NH.sub.2, NHR.sup.1 or NR.sup.1R.sup.2, R.sup.1 and R.sup.2 being, independently of one another, chosen from a alkyl, aryl, aralkyl, alkylaryl, alkoxy and aryloxy group, which may be linear, branched, cyclic, polycyclic, unsaturated, hydroxylated, carbonylated, phosphorylated and/or sulfurized, said group possibly possessing in its backbone a heteroatom particularly O, S and/or or N, and Pro* corresponding to Proline, an analogue or derivative thereof; comprising, for example, Myr-PPL-OH and Myr-PPR—OH.

[0211] Here can further be cited also the propigmenting and/or pro-mec dipeptides and tripeptides of general Formula X—(Xaa1)n—Pro*—Xaa2—Y disclosed in WO2014/080376, with n=0, 1 or 2, Xaa1 an hydrophobic aminoacid selected from Ala, Val, Met, Leu, Iso, Phe, Pro, and analogs and derivatives thereof, or a polar aminoacid selected from Ser, Thr, Tyr, Asp, Glu and analogs and derivatives thereof; and when n=2 the two aminoacids Xaa1 being the same or different; Xaa2 being an hydrophobic aminoacid selected from Ala, Val, Met, Leu, Iso, Phe, and analogs and derivatives thereof, or a basic aminoacid selected from Arg, Lys, His, and analogs and derivatives thereof; at the N terminal end X being selected from H, —CO—R.sup.1 and —SO.sub.2-R.sup.1; at the C terminal end Y being selected from OH, OR.sup.1, NH.sub.2, NHR.sup.1 or NR.sup.1R.sup.2; R.sup.1 and R.sup.2 being, independently from each other, selected from an alkyl, aryl, aralkyl, alkylaryl, alkoxy et aryloxy group, that can be linear, branched, cyclic polycyclic, saturated, unsaturated, hydroxylated, carbonylated, phosphorylated and/or sulfured, said group having or not an O, S and/or N heteroatom in its skeleton and Pro* corresponding to a Proline, analog or derivative thereof; comprising for example the following peptides Pal-SPR—OH, Pal-PPR—OH, Pal-QPA-OH, Pal-LPA-OH, Myr-SPA-OH, Pal-PM-OH, Pal-PA-OH and Pal-PP—OH.

[0212] Suitable tetrapeptide derivatives for use as additional peptides according to the present invention include, but are not limited to, Pal-KTFK (SEQ ID No 8) or Ela-KTFK (SEQ ID No 20), Ela-KTAK (SEQ ID No 21), Ela-KAYK (SEQ ID No 22) or Ela-KFYK (SEQ ID No 23).

[0213] Suitable pentapeptide derivatives for use as additional peptides herein include, but are not limited to, Pal-KTTKS (SEQ ID No 1) (available as Matrixyl® from Sederma), Pal-YGGFXaa (SEQ ID No 24) with Xaa being Leu or Pro, or mixtures thereof.

[0214] Suitable hexapeptide derivatives for use herein include, but are not limited to, Pal-VGVAPG (SEQ ID No 3), Pal-GKTTKS (SEQ ID No 6), Pal-HLDIIXaa with Xaa being Trp, Phe, Tyr, Tic, 7-hydroxy-Tic ou Tpi (SEQ ID No 25) and derivatives thereof. The mixture of Pal-GHK and Pal-GQPR (SEQ ID No 2) (Matrixyl® 3000, Sederma) can also be mentioned.

[0215] The following marketed peptides can be mentioned as well as additional active ingredients: Vialox™ (INCI name=Pentapeptide-3 (synthetic peptide comprising alanine, arginine, isoleucine, glycine and proline)), Syn-ake™ (β-Ala-Pro-Dab-NH-Bzl) or Syn-Coll™ (Pal-Lys-Val-Lys-OH) marketed by Pentapharm;

[0216] Argireline™ (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH.sub.2 (INCI name=Acetyl hexapeptide-3) (SEQ ID No 26), Leuphasyl™ (Tyr-D-Ala-Gly-Phe-Leu) (SEQ ID No 27), Aldenine™ (Gly-His-Lys), Trylagen™ (INCI name=Pseudoalteromonas Ferment Extract, Hydro lyzed Wheat Protein, Hydro lyzed Soy Protein, Tripeptide-10 Citrulline (reaction product of Citrulline and Tripeptide-10 (synthetic peptide constituted of aspartic acid, isoleucine and lysine)), Tripeptide-1), Eyeseryl™ (Ac-β-Ala-His-Ser-His)(SEQ ID No 28), Serilesine™ (Ser-Ile-Lys-Val-Ala-Val) (SEQ ID No 29) or Decorinyl™ (INCI name: Tripeptide-10 Citrulline=reaction product of Citrulline and Tripeptide-10 (synthetic peptide constituted of aspartic acid, isoleucine and lysine) marketed by Lipotec; Collaxyl™ (Gly-Pro-Gln-Gly-Pro-Gln (SEQ ID No 30)) or Quintescine™ (Cys-Gly) marketed by Vincience;

[0217] Cytokinol™LS (casein hydrolysate) marketed by Les Laboratoires Serobiologiques/Cognis; Kollaren™ (Gly-His-Lys), IP2000™ (Pal-Val-Tyr-Val) or Meliprene™ (INCI name=Monofluoroheptapeptide-1: reaction product of acetic acide and a synthetic peptide comprising arginine, glycine, glutamic acid, histidine, norleucine, p-fluorophenylalanine and tryptophan) marketed by l′lnstitut Europeen de Biologie Cellulaire;

[0218] Neutrazen™ (Pal-His-D-Phe-Arg-NH.sub.2) marketed by Innovations; or

[0219] BONT-L-Peptide™ (INCI name=Palmitoyl Hexapeptide-19: reaction product of palmitic acid and Hexapeptide-19 (synthetic peptide constituted of asparagine, aspartic acid, lysine and methionine), Timp-Peptide™ (INCI name=Acetyl Hexapeptide-20: reaction product obtained by acetylation of Hexapeptide-20 (synthetic peptide constituted of alanine, glycine, lysine, valine and proline) or ECM Moduline™ (INCI name=Palmitoyl Tripeptide-28: reaction product of palmitic acid and Tripeptide-28 (synthetic peptide constituted of arginine, lysine and phenylalanine) marketed by lnfinitec Activos.

[0220] It is also possible to combine the invention peptide(s) with one or more cyclic peptides, in particular those extracted from linseed oil described in the Applicant's patent application FR1850845.

[0221] Different compositions/formulations according to the invention are described below with examples of additional active ingredients.

[0222] The active ingredient according to the invention is as described in point C/comprising 100 ppm of peptide(s) according to the invention.

[0223] This ingredient is generally formulated within a range of 1 to 5%, preferably 3%.

[0224] 1—Cream Form, for Example an Antiageing Day Cream for the Face.

TABLE-US-00019 TABLE 19 Ingredients INCI name Role % Part A: H.sub.2O / / qsp100 Carbopol ™ Ultrez 10 Carbomer Thickener/Gelling agent 0.30 Part B: Brij S2-SS-(RB) ™ Steareth-2 Emulsifier 0.40 Brij S10-SO-(RB) ™ Steareth-10 Emulsifier 1.20 Crodafos CES-PA-(RB) ™ Cetearyl Alcohol (and) Emulsifier/conditionner 4.00 Dicetyl Phosphate (and) Ceteth-10 Phosphate Crodacol CS90-PA-(RB) ™ Cetearyl Alcohol Emollient 1.50 Laurocapram Laurocapram Emollient 2.50 Crodamol ™ AB-LQ-(RB) C12-15 Alkyl Emollient 1.50 Benzoate Crodamol ™ OSU-LQ-(JP) Diethylhexyl Succinate Emollient 7.00 Part C: Glycerin Glycerin Humectant 2.50 Octanediol Caprylyl Glycol Humectant/Emollient 0.50 Part D: Phenoxyethanol Phenoxyethanol Preservative qs Part E: Potassium sorbate Potassium Sorbate Preservative qs Part F: H.sub.2O / / 4.00 NaOH 30% Sodium Hydroxide pH adjuster 0.40 Part G: Ingredient according to the / Active 3.00 invention

[0225] Example(s) of Additional Active Ingredient(s): [0226] a moisturizing and smoothing ingredient such as: OPTIM HYAL™, marketed Sederma, comprises oligosaccharides of acetylated glucuronic acids having a structure similar to fragments of hyaluronic acid. [0227] a sebum-regulating ingredient such as: [0228] SEBULESS™, marketed by Sederma, comprising a Syringa vulgaris extract obtained by in vitro cell culture, acting as a purifying sebum regulator, mattifying and refreshing complexion, and bluring skin imperfections. [0229] PORETECT™, marketed by Sederma, comprising an association of linseed extract titrated in cylolinopeptides and a celery extract titrated in senkyunolides; this active acts on skin firmness, tone and density, thus strengthening the pore support structures sagging with age. [0230] In reinforcement of the activity: an ingredient acting on the skin elastic properties and the skin barrier such as: [0231] IDEALIFT™, marketed by Sederma, comprising the lipodipeptide N-acetyl-Tyrosyl-Arginyl-O-hexadecyl ester, combating facial flaccidity and improving resistance to gravity, in particular through elastin synthesis stimulation. [0232] DERMAXYL™, marketed by Sederma, combining ceramide 2, cement of the stratum corneum, and Pal-Val-Gly-Val-Ala-Pro-Gly, a palmitoylated matrikine which smoothes wrinkles and repairs the skin barrier. [0233] An anti-wrinkle/anti-aging ingredient based on pro-collagen peptide(s) such as: MATRIXYL™, MATRIXYL 3000™, MATRIXYL synthe′6™ and/or MATRIXYL Morphomics™ marketed by Sederma.

[0234] 2—Mild Aqueous Serum Form

TABLE-US-00020 TABLE 20 Ingredients INCI name Role % Part A: H.sub.2O / / qsp 100 Potassium sorbate Potassium Sorbate Preservative 0.10 Part B: Glycerin Glycerin Humectant 5.00 Phenoxyethanol Phenoxyethanol Preservative 0.80 Part C: Cromollient ™ SCE Di-PPG-2 Myreth-10 Adipate Emollient 1.20 VisiaOptima ™ SE Sodium Polyacrylate (and) Rheology modifier 1.00 Ethylhexyl Cocoate (and) and emulsion stabiliser PPG-3 Benzyl Ether Myrisate (and) Polysorbate 20 Part D: H.sub.2O / / 0.80 NaOH 30% Sodium Hydroxide pH adjuster 0.08 Part C: Ingredient according to / Active 3.00 the invention

[0235] Example(s) of Additional Active Ingredient(s): [0236] an anti-aging active ingredient such as: [0237] SENESTEM™, marketed by Sederma, comprising plant cells obtained by in-vitro cell culture of Plantago lanceolata, which in particular improves skin viscoelastic properties and lightens senescence age spots. [0238] un antioxidant ingredient such as: [0239] MAJESTEM™, marketed by Sederma, based on leontopodium alpinum plant cells obtained by in-vitro cell culture titrated in leontopodic acid; neutralizing oxidative stress (pollution and UV radiation) and restoring skin tension.

[0240] 3—Gel Form

TABLE-US-00021 TABLE 21 Ingredients INCI name Role % Part A: H.sub.2O / / qsp 100 Carbomer / Rheology 0.40 modifier Part B: Glycerin Glycerin Humectant 7.00 Phenoxyethanol Phenoxyethanol Preservative 0.80 Part C: H.sub.2O / / 3.00 NaOH 30% Sodium Hydroxide pH adjuster 0.30 Part D: Tween ™ 20 Polysorbate 20 Emulsifier 0.50 Cromollient ™ SCE Di-PPG-2 Myreth-10 Adipate Emollient 1.00 Covi-ox ™ Tocopherol (and) Helianthus Antioxidant 0.40 Annuus (Sunflower) Seed Oil Part E: Ingredient according to / Active 3.00 the invention

[0241] Example(s) of Additional Active Ingredient(s): [0242] an “antipollution” ingredient such as: [0243] CITYSTEM™, marketed by Sederma, based on plant cells obtained in vitro from Marrubium vulgare with a high concentration of Forsythoside B; used against pollution attacks: makes the skin soft and smooth, refines the skin texture, reduces the visibility of blackheads, leaving the skin radiant and purified. [0244] a calming ingredient for sensitive skin such as: [0245] PACIFEEL™, marketed by Sederma, comprising an extract of Mirabilis Jalapa. [0246] A moisturizing ingredient such as: [0247] AQUALANCE™, marketed by Sederma, an osmoprotective moisturizer composed of homarin and erythritol.

[0248] 4—Gel Form to Realize a Spray Mask

TABLE-US-00022 TABLE 22 Ingredients INCI name Role % Part A: H.sub.2O / / qsp 100 Hydrotriticum PVP PE ™ Aqua (and) Hydrolyzed Wheat Film-forming 3.00 Protein/PCP Crosspolymer agent Volarest ™ FL Acrylates/Beheneth-25 Rheology 2.30 Methacrylate Copolymer modifier Potassium sorbate Potassium Sorbate Preservative Part B: Glycerin Glycerin Humectant 5.00 Phenoxyethanol Phenoxyethanol Preservative 0.80 Part C: Crovol ™ A70 PEG-60 Almond Glycerides Emollient 1.00 Ethanol Ethanol Solvent 5.00 Covi-ox ™ Tocopherol (and) Helianthus Antioxidant 0.20 Annuus (Sunflower) Seed Oil Part D: H.sub.2O / / 2.50 NaOH 30% Sodium Hydroxide pH adjuster 0.25 Part E: Ingredient according to Active 3.00 the invention

[0249] Example(s) of additional active ingredient(s): [0250] an ingredient acting on the radiance of the complexion such as: [0251] EVERMAT™, marketed by Sederma, comprising a combination of an extract of Enantia chlorantha rich in protobberberins and oleanolic acid; decreases the pore size and skin shine; refines the texture of acne-prone skin. [0252] an ingredient with revitalizing properties such as: [0253] Fruitliquid™ Kumquat™, marketed by Crodarom.

[0254] 5—Cream Form, for a Make-Up Base

TABLE-US-00023 TABLE 23 Ingredients INCI name Role % Part A: H.sub.2O / / qsp 100 Volarest ™ FL Acrylates/Beheneth-25 Methacrylate Rheology 0.90 Copolymer modifier Part B: Arlacel ™ 2121 Sorbitan Stearate (and) Sucrose Emulsifier 4.50 Cocoate) Partie C : Pentylène glycol Pentylene Glycol Humectant 5.00 Phénoxyéthanol Phenoxyethanol Preservative 0.80 Partie D : Crodamol ™ SSA Decyl Isostearate (and) Isostearyl Emollient 2.00 Isostearate Crodamol ™ TN Isotridecyl Isononanoate Emollient 2.00 Crodamol ™ AB C12-C15 Alkyl Benzoate Emollient 1.50 Crodamol ™ GTEH Triethylhexanoin Emollient 3.00 Covi-ox ™ Tocopherol (and) Helianthus Annuus Antioxidant 0.10 (Sunflower) Seed Oil Part D: Potassium sorbate Potassium Sorbate Preservative 0.10 Part E: H.sub.2O / / 2.50 NaOH 30% Sodium Hydroxide pH adjuster 0.25 Part E: Ingredient according Active 3.00 to the invention

[0255] Example(s) of additional active ingredient(s): [0256] An ingredient for treating under eye bags and dak circles such as: HALOXYL™, marketed by Sederma, a combination of two matrikines, the Pal-GHK and the Pal-GQPR with N-hydroxysuccinimide and a flavonoid, the chrysin. [0257] EYELISS™, marketed by Sederma, combining three components: hesperidin methyl chalcone, the dipeptide Valyl-Tryptophan (VW) and the lipopeptide Pal-GQPR. [0258] PRODIZIA™, marketed by Sederma, comprising an extract of Albizia julibrissin, which promotes the visible reduction of signs of fatigue: dark circles, under eye bags, dull complexion and drawn features by repairing and protecting the skin from damage caused by glycation. [0259] An anti-wrinkle/anti-aging ingredient based on pro-collagen peptide(s) such as: [0260] MATRIXYL™, MATRIXYL 3000™, MATRIXYL synthe′6™ and/or MATRIXYL Morphomics™ marketed by Sederma.

[0261] 6—Cream Form, for Example for Treating an Acne Prone Skin (Cream Used for the In Vivo Efficacy Tests Given Below)

TABLE-US-00024 TABLE 24 Ingredient INCI name Role % Part A demineralized water Aqua / qsp 100 Carbopol Ultrez 10 ™ Carbomer Thickener/Gelling agent 0.45 Part B Glycerin Glycerin Humectant 2.00 Octanediol Caprylyl Glycol Humectant/Emollient 0.50 Part C Phenoxyethanol Phenoxyethanol Preservative qs Part D Squalane Squalane Emollient 3.00 Crodamol AB ™ C12-15 Alkyl Benzoate Emollient 2.00 Pemulen TR2 ™ Acrylates/C10-30 Alkyl Emulsifier 0.20 Acrylate Crosspolymer Part E Potassium sorbate Potassium Sorbate Preservative qs Part F Demineralized water Aqua / 5.00 NaOH 30% Sodium Hydroxide pH adjuster 0.50 Part G Ingredient according to the Active 1.00 invention Part H Tween 20 Polysorbate 20 Emusifier 1.00 Perfume Fragrance / 0.10

[0262] Example(s) of additional active ingredient(s): [0263] An ingredient for treating more specifically epidermis, such as: [0264] CRYSTALIDE™, marketed by Sederma, comprising the Pal-KTFK peptide in a solvated form. [0265] An ingredient for resynchronising the skin against digital pollution damage such as: [0266] SYNCHROLIFE™, marketed by Sederma, comprising chrysin, rosmarinic acid and the Pal-GQPR peptide. [0267] An ingredient for lightening skin such as: [0268] LUMISKIN™, marketed by Sederma, comprising a noraporphine derivative. [0269] An ingredient for treating hormonal facial skin sagging such as: [0270] FEMINAGE™, marketed by Sederma, comprising a plant extract of the Engelhardtia chrysolepsis.

[0271] E—In-vivo efficacy tests

[0272] The efficacy evaluation of the peptide(s) according to the invention was carried out at 28 and 56 days, on a total of 48 volunteers, in two independent studies against placebo. The effect on various imperfections of acne-prone skins: atrophic scars (in depth residual scars), residual-coloured marks (red and/or brown traces), inflammatory lesions (created or left by acneic phenomenons, such as pimples or pustules), roughness, redness overall skin uniformity, were evaluated thanks to these studies.

[0273] The objective of the first study was to quantify the cutaneous imperfections using a multiparameter 2D-3D camera and an expert evaluation on photos.

[0274] The second study associated an evaluation by a dermatologist, an image analysis on standardized photos and the perceived effect by the volunteers. The synopsis of these studies is shown on the below:

TABLE-US-00025 TABLE 25 T0 T 28 days T 56 days Expert evaluation on Expert evaluation on photos photos 2D-3D camera evaluation 2D-3D camera evaluation Dermatologist evaluation Dermatologist evaluation Dermatologist evaluation Perceived effect Perceived effect Image analysis Image analysis

[0275] Used Cream:

[0276] The cream formula 6 (Table 24) given in the above Galenical part, the placebo cream comprising the same formula without the active ingredient according to the invention (comprising 1200 ppm of Pal-KTSKS-OH, 2HCl).

[0277] 1) First Study:

[0278] Protocol:

[0279] Panel description: the study was carried out on a panel of 18 volunteers (17 women and 1 man) of average age 32 years (20-58 years) and of phototype II to IV. They had an oily skin with atrophic acne scars and almost all acne lesions. None of them were undergoing specific treatment for acne-prone skin.

[0280] Study type, duration, and applications: single-blind study, the volunteers using twice a day on the half of the face the cream according to the invention or its placebo; the applications lasted two months with an intermediate time of one month.

[0281] Statistics: for the imperfection quantification, statistical studies were performed with a Student t test or if necessary with a nonparametric Wilcoxon test. Bilateral tests were carried out on paired series.

[0282] For the expert assessment: a Khi2 test was used to compare response frequencies.

[0283] Methods and Results:

[0284] Expert Evaluation on Photos:

[0285] A photographic bench was used to acquire the photos to ensure perfect repositioning at each stage of the study. For each volunteer, profile photos were taken in a parallel polarized mode, therefore with shine, to obtain a clearer view of the relief in depth (acne-related scars) while visualizing the other imperfections (acne lesions in height and residual marks).

[0286] The obtained photos were assessed by a panel of six expert judges. For each volunteer, the experts viewed the photos before and after treatment and gave their opinion on the following statement: the product has reduced the imperfections (acne-related scars, residual marks and lesions). The responses reflect 43% favorable opinions in favor of the cream according to the invention, which is significantly higher than the 21% favorable opinions for the placebo.

[0287] Evaluation Using a Multiparametric Camera:

[0288] A portable LED camera illuminating in the visible at seven wavelengths was used. In addition, the skin surface was illuminated from different angles, allowing the image to be reconstructed in three dimensions. Polarizing filters were used to remove the shine and the use of a ALS (Ambient Light Substraction) algorithm ensured complete independence from external lighting. Acquisition without skin contact provides a measurement field of 5.6×5.6 cm with lateral (x-y) resolution of 0.1 mm and vertical (z) resolution of 0.01 mm.

[0289] This system allows a multi analysis of: [0290] the L* a* b* color parameter (L* value indicates lightness, and a* and b* are chromaticity coordinates); [0291] The chromophore concentrations such as hemoglobin and melanin; and [0292] Various topographies such as texture, pore volumes, scars or lesions

[0293] Results on Skin Smoothing:

[0294] Atrophic scars were particularly targeted in the analysis area.

[0295] The reliefs in height (inflammatory lesions and pimples), in depth (atrophic scars) as well as the global roughness, to follow a smoothing of the skin, were studied.

TABLE-US-00026 TABLE 26 Variation in the volume of lesions and scars (N = 18 volunteers) Volume of the lesions (in mm.sup.3) Volume of the scars (in mm.sup.3) Invention Placebo Invention Placebo T0 T56 T0 T56 T0 T56 T0 T56 Mean 2.12 1.29 3.07 2.92 3.86 2.97 4.37 4.19 Standard deviation 1.78 1.25 2.72 2.49 2.69 2.34 3.60 3.51 % variation vs. T0 −39.2% −4.9% −23% −4.1% Significativity p < 0.01 nsd p < 0.01 nsd Maximum −96% −86% Responders  94% 100% Significativity vs. <0.05 <0.01 Placebo

TABLE-US-00027 TABLE 27 Variation of the global roughness (N = 18 volunteers) Global roughness (in μm) Invention Placebo T0 T56 T0 T56 Mean 11.42 10.50 11.84 11.65 Standard deviation 2.55 2.78 3.45 3.34 % variation vs. T0 −8.1%  −1.6% Significativity p < 0.01 nsd Maximum −25% Responders 100% Significativity vs. Placebo p < 0.01

[0296] A significant decrease in lesions and scars is observed with the application of the cream according to the invention while the placebo has no significant effect. Skin smoothing is thus clearly demonstrated thanks to the invention cream, which is confirmed with the overall roughness parameter which shows a reduction of 8.1%.

[0297] Results on Redness:

[0298] Two parameters were highlighted: maximum redness, which is the most effective parameter to see a reduction in severe redness of the lesion-type, and the heterogeneity of redness which quantifies the extent of redness in the analyzed surface.

TABLE-US-00028 TABLE 28 Variation of redness (N = 18 volunteers) Concentration/ Maximum redness Redness heterogeneity Heterogeneity Invention Placebo Invention Placebo (in arbitrary units) T0 T56 T0 T56 T0 T56 T0 T56 Mean 44.96 39.48 43.15 40.93 2.87 2.52 2.82 2.67 Standard deviation 12.62 12.95  8.86  9.09 1.32 1.13 1.10 0.96 % Variation vs. T0 −12.2% −5.2% −12.0% −5.4% Significativity p < 0.01 nds p < 0.01 nds Maximum −36% −31% Responders  89%  72% Significativity vs. p < 0.05 p < 0.05 Placebo

[0299] The association of a decrease of the maximum redness with a reduction in heterogeneity makes residual marks or inflammatory lesions less visible and the complexion more uniform.

[0300] 2) Second Study

[0301] Protocol:

[0302] Panel description: the study was carried out on a panel of 30 volunteers (7 men and 23 women) of average age 24 years (18-39 years), of phototype III and with oily or mixte skin. They all had an oily skin with inflammatory lesions, residual red or brown traces, and most (26) had atrophic acne scars grade 2-4 on the Goodman scale. None of them were undergoing specific treatment for acne-prone skin.

[0303] Type of Study, Duration, and Applications:

[0304] For this single-blind study, the volunteers used the cream according to the invention or its placebo twice a day on the half of the face. The applications lasted 2 months with an intermediate time of 1 month.

[0305] Statistics:

[0306] For the clinical evaluation, a linear mixed-effects model was used which is suitable for unbalanced designs (missing datas as 3 panelists were missing at T2months). The analysis was therefore performed on the set of subjects, whether or not they have missing data. This part makes it possible to say whether there is globally a product effect, a time effect, and a product x time interaction. Subsequently, in a more conventional fashion, pairwise comparisons were made using a post-hoc Tukey test.

[0307] For the image analysis and the effect perceived by the volunteers, a Khi2 test was used to compare the response frequencies.

[0308] Methods and Results:

[0309] Clinical Evaluation

[0310] It was carried out at T0, T28 and T56 by the same dermatologist for each half-face while respecting a standardized position and lighting of the volunteer.

[0311] A count of the inflammatory lesions (pimples and pustules) was carried out according to the method of Lucky et al. Each type of imperfection was counted on the following areas: forehead, cheeks, and chin (right and left side excluding the nasal pyramid, vermilion border, chin crease and scalp edge). Residual marks (red and brown) were counted similarly.

[0312] Regarding atrophic scars, the dermatologist assessed their severity on a scale of 0 (no scars) to 9 (scars of severe intensity in relation to their appearance and number).

TABLE-US-00029 TABLE 29 Variation of inflammatory lesions and residual marks (N = 30 volunteers at T28, 27 volunteers at T56) Inflammatory lesions Numbers Invention Placebo of lesions T0 T28 T56 T0 T28 T56 Mean 10.5 6.1 4.7 10.6 8.5 7 Standard deviation  6.2 4.3 4.3  5.9 4.4 5.2 % Variation vs. T0 −42% −55% −20% −34% Significativity p < 0.01 p < 0.01 p = 0.06 p < 0.01 Maximum; −100%; −100%; Responders 90% 93% Significativity p < 0.05 p < 0.05 vs. Placebo

TABLE-US-00030 TABLE 30 Variation of the residual marks (N = 30 volunteers at T28, 27 volunteers at T56) Residual marks Numbers Invention Placebo of marks T0 T28 T56 T0 T28 T56 Mean 15.7 12.3 11.6 15.4 14.6 13.9 Standard deviation  8.6  6.8  7.1  7.8  6.8  5.7 % Variation vs. T0 −22% −26% −5% −10% Significativity p<0.01 p<0.01 nds nds Maximum; Responders −75%; −87%; 87% 89% Significativity p = 0.08 p = 0.12 vs. Placebo

TABLE-US-00031 TABLE 31 Variation of atrophic scars (N = 30 volunteers at T28, 27 volunteers at T56) Severity of the atrophic scars Score of the atrophic Invention Placebo scars (0 to 9) T0 T28 T56 T0 T28 T56 Mean 4.6 4.2 3.7 4.4 4.3 4.1 Standard deviation 1.5 1.6 1.4 1.6 1.6 1.6 % variation vs. T0 −9% −20% −2% −7% Significativity p < 0.05 p < 0.01 nds p = 0.09 Maximum; Responders −33%; −40%; 33% 67% Significativity vs. Placebo nds p < 0.05

[0313] These results show that the application of the cream of the invention causes a significant reduction in lesions, residual marks and scars. These effects, present as early as 28 days, are accentuated after 56 days of treatment and are significantly greater and globally significant compared to those provided by the placebo.

[0314] Image Analysis on Standardized Photos

[0315] The standardized photos were taken with a HeadScan Dynamics System II (OrionTechnoLab, France) equipped with a professional camera and a high resolution (24 Mpx) sensor. Photos in cross-polarized and scattered light were obtained with an automatic system for positioning different filters. Subject repositioning during the different study stages was ensured by a restraint device and a laser line projected on the corners of the mouth.

[0316] The image analysis used in the study tracked the number of inflammatory lesions and their intensity. The results below show the % of volunteers who saw improvement in their condition.

TABLE-US-00032 TABLE 32 Improvement in the number and intensity of the lesions after 56 days of treatment (in % of volunteers; N = 27 volunteers) Numbers and intensity of Numbers of lesions Intensity of the lesions the lesions Invention Placebo Invention Placebo Invention Placebo 70.4%* 55.6% 74.1%*.sup.$ 33.3% 51.9%.sup.$ 18.5% *significant variation vs. T0 with p < 0.05, .sup.$significant variation vs. Placebo with p < 0.05

[0317] Among the volunteers who applied the cream according to the invention, 70.4% had a decrease in the number of lesions, 74.1% a decrease in the intensity of the lesions and 51.9% the combination of the two, against only respectively 55.6%, 33.3% and 18.5% for the placebo.

[0318] Effect perceived by volunteers: perceived effect was assessed using a self-report questionnaire after 28 days of treatment.

TABLE-US-00033 TABLE 33 For each statement, the volunteers had to choose from the following answers: Totaly agree Grouped into « favorable opinion » Agree Disagree Grouped into « defavorable opinion » Totaly disagree

TABLE-US-00034 TABLE 34 Perceived efficacy after 28 days of treatment (in % of favorable opinions; N = 30 volunteers) Less scars Attenuated scars Less rednesses Less visible pores Invention Placebo Invention Placebo Invention Placebo Invention Placebo 92%.sup.$ 38% 92%.sup.$ 62% 100%.sup.$ 83% 97%.sup.$ 57% Less imperfections More uniform skin Less rednesses Invention Placebo Invention Placebo Invention Placebo 83%.sup.$ 50% 97%.sup.$ 73% 83%.sup.$ 37% .sup.$Significant variation vs. placebo with p < 0.05

[0319] The results show an efficacy of the cream according to the invention that is systematically greater than the placebo and shows a perceived effect in terms of scars (92%), residual marks and imperfections (83%), pores and skin uniformity (97%) as well as rednesses (100%).

[0320] All these in vivo results show that the peptide(s) according to the invention can embellish the skin by acting on all type of cutaneous imperfections in relief and in colours, in particular imperfections that are due to residual scars and marks, more particularly due to acne episodes.